Metastatic Melanoma, BRAF V600 Mutation Positive
Conditions
Keywords
Melanoma, BRAF V600, HRQoL, PROs, Encorafenib, Binimetinib, Real-World, prospective
Brief summary
This is a prospective longitudinal multi-centre observational study conducted in the United Kingdom, in patients with metastatic cutaneous BRAF V600 mutation-positive melanoma assigned to receive encorafenib and binimetinib. The aim of this study is to learn about how encorafenib and binimetinib perform, patients' experiences of using them, and how they might affect patient's quality of life, in the real world, when these treatments are prescribed by doctors instead of in a clinical trial. Participants will complete electronic data entry via questionnaires over a 24-month period. Site research teams will also complete electronic data entry using participants' medical records over a 24-month period.
Detailed description
This longitudinal study will collect real-world clinical outcomes and patient-reported outcomes (PRO) data for patients receiving encorafenib plus binimetinib. The results from the study will be summarized descriptively to describe the impact of encorafenib plus binimetinib in the UK real-world setting. The COLUMBUS trial has demonstrated the efficacy and safety profile of encorafenib plus binimetinib in patients with advanced melanoma with a BRAFV600 mutation; the 7-year analysis of this study is currently available. Real-world studies can reach broader patient populations than are typical of clinical trials, and also provide unique insights, such as real-life challenges faced by patients, the impact of a disease on productivity, and daily disease management. Given the importance of patient health-related quality of life (HRQoL) data in melanoma treatment and the potential value of real-world evidence (RWE), Pierre Fabre wishes to complement the clinical and HRQoL outcomes demonstrated for encorafenib plus binimetinib in the COLUMBUS trial with patient-reported outcomes (PROs) data from a real-world study. The source population will be patients being treated for melanoma in National Health Service (NHS) England secondary care centers at the time of study enrolment. Approximately 8 study sites will be selected from the available secondary care centers, based on clinical experience with encorafenib plus binimetinib, research capacity, and willingness to take part. Patients who are interested in participating in the study will be able to download the Vitaccess Real™ application either during their consultation at the site or at their own convenience. After completing the in-application informed consent process, they will be able to begin data entry via the application. Site research teams will complete an electronic case report form (eCRF) for each participant at baseline, using data from the participant's electronic medical record (EMR). For analysis purposes, data from the eCRF will be linked to the participant-reported data using the participant's assigned unique ID and PIN number.
Interventions
BIOLOGICALEncorafenib + Binimetinib
Participants will have received a clinical decision to begin encorafenib plus binimetinib treatment as a second-line treatment for metastatic melanoma, in accordance with current Summary of Product Characteristics
Sponsors
Vitaccess Ltd
Pierre Fabre Ltd
Study design
Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged 18 years or older * Willing and capable of providing written informed consent * Access to a smartphone * Diagnosis of metastatic cutaneous melanoma with presence of BRAF V600 mutation in tumour tissue prior to enrolment * Clinical decision has been made to begin encorafenib plus binimetinib treatment in accordance with current Summary of Product Characteristics * Encorafenib plus binimetinib to be prescribed as second-line treatment for BRAF V600-mutant metastatic melanoma
Exclusion criteria
* Patients receiving systemic treatment for any tumours other than melanoma * Patients participating in a clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Describe the change from baseline over 24 months of FACT-Melanoma (FACT-M) scores of patients initiated on encorafenib plus binimetinib | Every eight weeks (±7 days) from baseline for first 6 months; every 3 months (±7 days) thereafter for the remaining 18 months (24 months total) | FACT-M instrument data reported by patients via the Quality of Life - Melanoma in the UK (QOL-MUK) platform (Impact of melanoma on well-being survey). The FACT-M contains 24-items reported on a 5-point Likert-type scale (Not at all, A little bit, Somewhat, Quite a bit, and very much). The outcome measure contains the 3 QoL domains; 20 items relate to physical well-being, 3 to emotional well-being, and 1 to social well-being. The higher the score, the better the quality of life (QOL). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Describe patient baseline clinical characteristics | Once, at baseline | Assessed using electronic medical record (EMR) data reported by healthcare professionals (HCPs) (Disease history, Statuses and Treatment history surveys). |
| Describe median duration of treatment with encorafenib and binimetinib | Every three months (±7 days) for 24 months, starting three months from baseline | Assessed using electronic medical record (EMR) data reported by healthcare professionals (HCPs) (Treatment history and Treatment status surveys). |
| Describe change from baseline over 24 months of EQ-5D-5L scores of patients receiving encorafenib plus binimetinib | Every eight weeks (±7 days) from baseline for first six months; every three months (±7 days) for the remaining 18 months (24 months total) | EQ-5D-5L instrument data reported by patients via the QOL-MUK platform (General health survey). The instrument comprises two parts. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels (1 - no problems, 2 - slight problems, 3 - moderate problems, 4 - severe problems, and 5 - extreme problems). The digits for 5 dimensions can be combined in a 5-digit number describing the health state of the person. |
| Describe changes in patient self-reported symptom severity over 24 months using the Patient Global Impression of Severity (PGI-S) | Every eight weeks (±7 days) from baseline for first six months; every three months (±7 days) for the remaining 18 months (24 months total) | PGI-S instrument data will be reported by patients via the QOL-MUK platform (Symptom severity survey). This is a generic instrument used to assess self-perceived severity of a specific condition, with the following response options: None, Mild, Moderate, Severe, Very Severe. |
| Describe the median time from baseline to definitive 10% deterioration of the FACT-M scores of patients receiving encorafenib plus binimetinib using Kaplan-Meier analysis | Every eight weeks (±7 days) from baseline for first six months; every three months (±7 days) for the remaining 18 months (24 months total) | FACT-M instrument data reported by patients via the QOL-MUK platform (Impact of melanoma on well-being survey). A 10% deterioration is defined as a deterioration of at least 10% in total FACT-M score. The total FACT-M score ranges from 0 to 172. The higher the FACT-M score, the better the QOL. |
| Describe patient demographics | Once, at baseline | Assessed using demographic data reported by participants via the QOL-MUK platform (including; month and year of birth, sex and ethnicity). |
| Describe reasons why encorafenib plus binimetinib treatment may be discontinued | Every three months (±7 days) for 24 months, starting three months from baseline | Assessed using electronic medical record (EMR) data reported by healthcare professionals (HCPs) (Treatment status survey). |
| Describe real-world progression-free survival (PFS) and overall survival (OS) of patients receiving encorafenib plus binimetinib using Kaplan-Meier analysis | Every three months (±7 days) for 24 months, starting three months from baseline | Assessed using electronic medical record (EMR) data reported by healthcare professionals (HCPs) (Clinical outcomes survey). |
| Describe the presence of melanoma brain metastases (MBM) at the beginning of study and the development and/or progression of MBM in patients receiving encorafenib plus binimetinib | Every three months (±7 days) for 24 months, starting three months from baseline | Assessed using electronic medical record (EMR) data reported by healthcare professionals (HCPs) (Clinical outcomes survey), specifically whether melanoma has metastasized to brain since previous assessment; if new MBM, date of metastasis; if existing MBM, whether intracranial progression; if yes, date of intracranial progression. |
| Describe adverse events (AEs) experienced by patients receiving encorafenib plus binimetinib | Within 24 hours of becoming aware of AEs | This will be assessed via the contents of Pierre Fabre solicited AE collection form, including type of AE and grade/severity. |
| Describe the median time from baseline to definitive 10% deterioration of the EQ-5D-5L scores of patients receiving encorafenib plus binimetinib using Kaplan-Meier analysis | Every eight weeks (±7 days) from baseline for first six months; every three months (±7 days) for the remaining 18 months (24 months total) | EQ-5D-5L instrument data will be reported by patients via the QOL-MUK platform (General health survey). A 10% deterioration is defined as a deterioration of at least 10% in the utility index score for EQ-5D-5L. EQ-5D-5L utility index scores range from 0 to 1; higher index scores indicate a higher health utility. |
Countries
United Kingdom
Contacts
Primary ContactMark J W Larkin, PhD
Backup ContactAkosua Ofori, MPH
Outcome results
None listed